Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Multiple Myeloma 8Neoplasms 7Colorectal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 6Ovarian Neoplasms 5Breast Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Glioma 4Cholangiocarcinoma 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Hematologic Neoplasms 3

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × Thyroid Carcinoma, Anaplastic × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡